| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
3,001 |
2,592 |
$615K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,577 |
1,390 |
$229K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
712 |
585 |
$179K |
| 87428 |
|
463 |
427 |
$26K |
| 71046 |
Radiologic examination, chest; 2 views |
326 |
277 |
$24K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
474 |
331 |
$20K |
| 80363 |
|
171 |
127 |
$15K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
908 |
521 |
$13K |
| 80053 |
Comprehensive metabolic panel |
1,988 |
1,662 |
$12K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
256 |
201 |
$12K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
875 |
803 |
$11K |
| 80347 |
|
170 |
126 |
$10K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
1,761 |
1,474 |
$10K |
| 80337 |
|
150 |
109 |
$7K |
| J3490 |
Unclassified drugs |
2,684 |
950 |
$7K |
| 80351 |
|
151 |
108 |
$7K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
522 |
341 |
$7K |
| 80321 |
|
142 |
99 |
$7K |
| 87081 |
|
1,046 |
926 |
$6K |
| 80370 |
|
171 |
127 |
$6K |
| 80373 |
|
171 |
127 |
$6K |
| 80368 |
|
164 |
123 |
$6K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
225 |
118 |
$5K |
| 80367 |
|
171 |
127 |
$5K |
| 80356 |
|
157 |
113 |
$5K |
| 80359 |
|
153 |
110 |
$5K |
| 80366 |
|
154 |
112 |
$5K |
| 80348 |
|
171 |
127 |
$5K |
| 80357 |
|
144 |
101 |
$4K |
| 80372 |
|
170 |
126 |
$4K |
| 80358 |
|
173 |
126 |
$4K |
| 80355 |
|
154 |
112 |
$4K |
| 80324 |
|
170 |
126 |
$4K |
| 80345 |
|
171 |
126 |
$4K |
| 80353 |
|
170 |
126 |
$4K |
| 80349 |
|
126 |
100 |
$3K |
| 80061 |
Lipid panel |
216 |
188 |
$3K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
69 |
59 |
$2K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
14 |
12 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
182 |
160 |
$2K |
| 83986 |
|
171 |
127 |
$1K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
61 |
26 |
$1K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
60 |
51 |
$1K |
| 84443 |
Thyroid stimulating hormone (TSH) |
94 |
79 |
$1K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
158 |
91 |
$1K |
| 81003 |
|
235 |
183 |
$1K |
| 71045 |
Radiologic examination, chest; single view |
31 |
27 |
$1K |
| 36415 |
Collection of venous blood by venipuncture |
1,013 |
686 |
$940.41 |
| 73630 |
|
16 |
13 |
$934.90 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
49 |
25 |
$757.06 |
| 81001 |
|
278 |
227 |
$534.51 |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
22 |
16 |
$517.75 |
| 81025 |
|
84 |
71 |
$511.34 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
32 |
24 |
$448.89 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
93 |
64 |
$440.37 |
| 83735 |
|
167 |
109 |
$429.64 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
65 |
48 |
$288.88 |
| 83874 |
|
64 |
55 |
$252.11 |
| A9150 |
Non-prescription drugs |
860 |
548 |
$247.05 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
72 |
64 |
$228.93 |
| 82553 |
|
63 |
55 |
$225.65 |
| 80305 |
|
25 |
25 |
$207.87 |
| 84484 |
|
68 |
56 |
$196.41 |
| 97161 |
|
12 |
12 |
$178.72 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
12 |
12 |
$126.86 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
71 |
50 |
$104.47 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
29 |
24 |
$79.60 |
| A4216 |
Sterile water, saline and/or dextrose, diluent/flush, 10 ml |
117 |
84 |
$49.68 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
12 |
12 |
$0.00 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
12 |
12 |
$0.00 |